EPICARDIAL WIRELESS PACEMAKER FOR IMPROVED LEFT VENTRICULAR RESYNCHRONIZATION (CONCEPTUAL DESIGN) by Hawkins, Rodney J
EPICARDIAL WIRELESS PACEMAKER FOR IMPROVED LEFT 
VENTRICULAR RESYNCHRONIZATION (CONCEPTUAL DESIGN) 
 
 
 
 
 
A Thesis 
presented to 
the Faculty of California Polytechnic State University, 
San Luis Obispo 
 
 
 
 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Master of Science in Engineering with Specialization in Biomedical Engineering 
 
by 
Rodney Hawkins 
December 2010 
 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2010 
Rodney John Hawkins 
ALL RIGHTS RESERVED 
 
 
 
 iii 
COMMITTEE MEMBERSHIP 
 
 
 
TITLE: Epicardial Wireless Pacemaker for Improved Left 
Ventricular Resynchronization (Conceptual 
Design) 
 
 
 
AUTHOR: Rodney Hawkins 
 
 
 
DATE SUBMITTED: December 2010 
 
 
 
COMMITTEE CHAIR:   Dr. Lanny Griffin, BMED Department Chair 
 
 
 
 
  
 
 
COMMITTEE MEMBER: Dr. Dan Walsh, BMED Professor 
 
 
 
  
 
 
 
 
COMMITTEE MEMBER: Dr. Robert Crocket, Director, General Engineering 
Program 
 
 
 
  
  
 
 iv 
Abstract 
 
Epicardial Wireless Pacemaker for Improved Left Ventricular Resynchronization 
(Conceptual Design) 
 
Rodney Hawkins 
 
   The human body is a well tuned mechanism where systems work in 
synergy to provide a healthy quality of life.  The human circulatory system 
transports oxygenated blood from the heart to the rest of the body delivering the 
proper nutrients for cells to function.  When the heart malfunctions, serious 
complications can arise leading to sudden cardiac arrest.  Congestive heart 
failure (CHF) is one heart disease that affects the synchrony of the heart’s 
ventricles. 
 Cardiac resynchronization therapy (CRT) has been widely accepted as a 
treatment for CHF.  Similar to traditional dual chamber pacing techniques, CRT 
adds a pacing lead to stimulate the left ventricle.  Left ventricular leads are 
implanted via the coronary sinus which provides the easiest surgical access to 
the left ventricle.  Another option for LV pacing is by using an epicardial lead.  
This option has proven to be safe and effective but requires major surgery.  An 
epicardial lead is usually implanted by performing a thoracotomy.  Many studies 
have been done to show the benefits of bi-ventricular pacing, therefore 
developing new methods to gain LV access safely and reliable are highly 
desirable. 
The epicardial satellite pacemaker, or EPI pacemaker, is a component of 
a larger CRT system.  This implantable cardiac system is composed of a master 
pacing unit with leads and a remote satellite pacing unit.  The master unit is a 
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traditional CRT device electrically coupled to the right side of the heart.  It 
controls the right atrium and ventricle via transvenous leads anchored to the 
endocardium of the heart.  The master device generates the pacing pulses to 
stimulate the right atrium and right ventricle and a communications module to 
transmit pacing commands to the epicardial satellite device.  The epicardial 
satellite pacemaker is a leadless device mounted directly on the epicardium of 
the left ventricle.  The epicardial pacemaker can be implanted using a 
thoracoscopic procedure during implant of the master unit.  In special events, it 
can be implanted using prophylactic techniques during heart bypass surgery of 
other surgical procedures where access to the heart is available.  Much work 
needs to be done to prove the technology.  But current RF communication 
capabilities in today’s devices offer the groundbreaking path to develop a satellite 
LV pacing design. 
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Chapter 1: Introduction 
 
 
 Congestive heart failure (CHF) is a disease that affects millions of people 
worldwide.  Every day more cases are diagnosed and if left untreated it can have 
deadly results.  Congestive heart failure is a disease affecting the ventricular 
synchrony of the heart.  In its advanced condition, the left ventricle may not pump 
enough blood out the heart producing a backfill in the lungs.  The lack of 
oxygenated blood to the body may also affect physiological function of the body 
diminishing the quality of life. 
 An accepted treatment for CHF has been cardiac resynchronization 
therapy (CRT).  This therapy was developed in the 1990’s and first commercially 
available with an implantable device in 2001.  CRT expands traditional pacing 
therapy of the right ventricle by including pacing stimulation to the left ventricle.  
This requires the addition of another transvenous lead to reach the left ventricle.  
The left ventricle chamber is not easily accessible, thus the coronary system 
provides the best approach for stimulation.  The coronary sinus is the avenue 
chosen by most physicians to gain access to the left side of the heart.  But 
anatomical differences within patients sometimes make it difficult for the 
implanting physician to reach the right site for optimal pacing results.  Other 
challenges encountered include lead dislodgement and/or higher pacing capture 
thresholds. 
 A wireless epicardial pacemaker moves away from traditional pacing 
therapy techniques and brings forward a concept for left ventricular pacing.  By 
 2 
taking advantage of today’s radio frequency capabilities within pacemakers and 
implantable cardioverter defibrillators, a wireless device communicating with a 
master device may be implanted directly to the epicardium of the left ventricle.  
This concept can be proved useful in solving LV access and ensuring the 
appropriate site and pacing threshold can be achieved for optimal LV function.  It 
may also provide additional benefits by allowing a plurality of epicardial 
pacemakers to be implanted to deliver multisite therapy. 
 It is important to have the basic understanding of the heart’s conducting 
system, as this is the fundamental model to replicate when designing systems to 
sense and pace the heart.  Research and development teams are constantly 
looking at new ways, methods, and locations to pace the heart in order to 
achieve optimal hemodynamic functionality.  Traditional methods of drugs and 
implantable devices have limitations that are constantly being improved with the 
introduction of new products.  Through an understanding of the heart’s anatomy, 
it may be clear that traditional left lead implants to provide left ventricular 
stimulation have many challenges that are patient dependent.  And that an 
alternate method to send an electrical impulse may be worth experimenting.  This 
thesis describes in detail the concept of a wireless epicardial pacemaker working 
as a satellite device receiving commands from a master device.  It addresses the 
benefits of this new technology as well as the unresolved challenges left for 
future work.  
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Chapter 2: The Heart 
 
 
2.1 The Circulatory System 
The circulatory system, along with the endocrine and nervous systems, 
make up the principle coordinating and integrating systems of the human body.  
Whereas the nervous system primary function is dealing with communication and 
the endocrine system with regulation of certain body function, the circulatory 
system function is to transport and distribute essential nutrients to the body’s 
cells and remove metabolic by-products.  It also serves as a control mechanism 
to regulate body temperature and adjustment of O2 and nutrients supply in 
different physiologic states. 
The circulatory (or cardiovascular) system accomplishes these functions 
by using a pump, a series of distributing and collecting tubes, and an extensive 
array of thin vessels that allow rapid exchange between the tissue and the 
vascular channels.  The pump mentioned above is the heart.  The heart consists 
of two pumps in series: the right heart and the left heart.  In turn, each of these 
hearts is a pulsing two chamber pump composed of an atrium and a ventricle.  
The atrium functions primarily as a weaker pump for the ventricle to help blood 
into the ventricle.  The ventricle then supplies the main force to propel the blood 
either to the lungs (right ventricle) or the rest of the body (left ventricle). 
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Figure 1 Cross Section of the Human Heart 
 
The right ventricle propels blood from the heart to the lungs for exchange 
of O2 and CO2.  This function is also known as the pulmonary circulation.  The left 
ventricle propels oxygenated blood to all other tissues of the body.  This function 
is known as the systemic circulation.  The flow of blood throughout the body is 
also unidirectional.  This is accomplished by systematically arranged flap valves 
that prevent blood from flowing backwards. 
 
2.2 The Heart Anatomy 
The human heart has a mass between 250 and 350 grams and is about 
the size of a fist.1  It is located in the chest area in front of the vertebral column 
and behind the sternum inside the rib cage for protection.  It is enclosed in a 
doubled-wall sac called the pericardium.  The outer part of this sac is called the 
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fibrous pericardium.  This sac also protects the heart, anchors to its surrounding 
structures, and prevents the heart from overfilling with blood.  The wall of the 
heart is composed of three layers, the epicardium, the myocardium, and the 
endocardium.  The outer layer is called the epicardium or visceral pericardium 
since it is also known as the inner wall of the pericardium.    The middle layer is 
the myocardium and it is composed of muscle that contracts.  This is the thickest 
layer and it is known as the “workhorse” of the heart.  The inner layer of the heart 
is the endocardium and it is composed of tissue that is in contact with the blood 
the heart pumps.  It has a smooth surface which allows easy blood flow 
throughout the heart chambers. See figures 2 and 3 below. 
 
 
Figure 2 Heart Muscle Tissue Layers31 
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Figure 3 Cross Section of Heart Wall2 
 
The heart has four chambers.  The upper chambers are known as the 
atria while the lower chambers are known as the ventricles. The right atrium 
receives deoxygenated blood from the body via the superior and inferior vena 
cava.  Blood is passed to the right ventricle through a valve where the blood is 
pumped to the lungs to collect oxygen.  In a similar fashion, oxygenated blood 
from the lungs returns to the left atrium and it is pumped through a valve to the 
left ventricle. The left ventricle pumps the oxygen rich blood to the rest of the 
body through the aorta. 
Blood flow within the four chambers of the heart is also unidirectional, from 
the atria to the ventricles and from the ventricles to the arteries.  This is 
accomplished by four valves within the heart (tricuspid, mitral, aortic, and 
pulmonary.1 
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Figure 4 Heart Chambers and Valves2 
 
The tricuspid valve separates the right atrium from the right ventricle whereas the 
mitral valve separates the left atrium from the left ventricle.  These two valves are 
also known as atrioventricular valves.  The pulmonary valve separates the right 
atrium from the pulmonary artery.  The aortic valve separates the left ventricle 
from the aorta.  These two valves are also known as semilunar valves. 
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Chapter 3: Electrophysiology of the Heart 
 
 
The nervous system controls various aspects of the cardiac function 
including the rate at which the heart beats and the strength of the contractions.  
However, cardiac function does not require a fully functional nervous system.  
The heart possesses properties of automaticity (the ability to initiate its own beat) 
and rhythmicity (the ability to regulate its pacemaking activity.) 3  Cells located in 
all four chambers of the heart are capable of initiating beats, although such cells 
reside primarily in the nodal tissues of the heart.  The region that ordinarily 
generates the greatest frequency of beats is the sinoatrial (SA) node.  This node 
is known as the “natural pacemaker” of the heart.  The electrical signals from the 
SA node travel through the atria to the atrioventricular node or AV node.  The 
conductive system is organized in such a way that the cardiac impulse does not 
travel too fast from the atria to the ventricles.  The AV node provides an electrical 
delay to allow the atria to empty the blood into the ventricles before ventricular 
contraction is initiated. 
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Figure 5 Cardiac Conduction System4 
 
After the delay, the AV node sends an electrical signal through the “bundle of his” 
to the bundle braches and then to the Purkinje fibers.  The action potential is then 
propagated to the endocardium at the apex of the heart and then to the 
ventricular myocardium which in turn contracts the ventricles.5  But other parts of 
the heart can exhibit rhythmic excitation in the same way the SA node fibers do.  
This is primarily true for the AV node and the purkinje fibers.  The AV node fibers 
when not stimulated from an outside source can discharge at an intrinsic rhythm 
of 40 to 60 beats per minute.  In a similar way, the Purkinje fibers can discharge 
at a rate between 15 to 40 beats per minute. 6  These rates are much lower than 
the intrinsic rhythm of the SA node at 70 to 80 beats per minute.6  This difference 
in frequency is why the SA node controls the heart rhythm and it is called the 
natural pacemaker of the heart.  Before the AV node or the Purkinje fibers can 
reach their own threshold for self excitation, the SA node emits a new impulse 
discharging both the AV node and the Purkinje fibers.  If the SA node would ever 
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fail, the AV node or Purkinje fibers at their low frequency output would not 
provide the necessary cardiac output required by the human body. 
Occasionally, other parts of the heart develop a rhythmical discharge rate 
that is much faster than the SA node.  Often enough this occurs on the AV node 
or the Purkinje fibers when these become abnormal.  In this instance, the natural 
pacemaker of the heart shifts from the SA node to the AV node or Purkinje fibers.  
Under rare conditions, a random point in the atria or ventricle develops excessive 
excitability and becomes the pacemaker, known as ectopic foci.  A pacemaker 
elsewhere than the SA node is called an “ectopic pacemaker”.6  An ectopic 
pacemaker causes an abnormal sequence of contractions of different parts of the 
heart and can lead to significant debilitating pump functionality.  If left untreated, 
it can develop more serious conditions like congestive heart failure. 
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Chapter 4: The Coronary System 
 
 
Perhaps the most common cause of congestive heart failure is coronary 
artery disease.  This disease is the narrowing of the small blood vessels that 
supply oxygenated blood to the heart.  A brief understanding of the coronary 
system and its physiology will give us a better understanding of the challenges 
today’s engineers face in developing new treatments for CHF.  
While the circulatory system is busy providing oxygen and nourishment to 
all the cells in the body, the heart is working its hardest pumping the blood.  And 
to work properly, the heart also needs blood and nourishment.  After all, the heart 
is another organ in the body.  The coronary system is the blood vessels within 
the heart that circulate blood to the heart and from the heart.  This system of 
blood vessels includes arteries and veins.  Arteries are blood vessels that carry 
oxygenated blood from the heart to the heart cells. Veins are blood vessels that 
bring back deoxygenated blood to the heart.  The coronary circulation refers to 
the movement of blood through the heart tissue.  The circulation of blood through 
the heart is just one part of the overall circulatory system of the body.7 
 
4.1 Coronary Circulation (How it Works) 
 
The heart muscle requires oxygen rich blood like any other organ in the 
body to function properly.  Blood is supplied to the heart by its own vascular 
system called the coronary circulation.   The aorta, the largest artery in the body, 
branches off into two main coronary blood vessels, the right coronary artery and 
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the left coronary artery.  These two arteries branch into smaller arteries and 
finally into capillaries which supply the oxygen rich blood to the heart tissue.  In a 
similar manner, the coronary veins bring back the oxygen free blood from the 
heart tissue back to the right side of the heart to be pumped into the lungs. 
The right coronary artery or RCS supplies blood to the right side of the 
heart.  The RCA lies in the right atrioventricular (AV) groove between the right 
atrium and right ventricle.  The left coronary artery or LCA itself branches into two 
separate arteries, the left anterior descending artery (LAD) and the circumflex 
artery. 
 
 
 
Figure 6 Coronary Arteries of the Heart30 
 
These two arteries supply the left side of the heart with oxygen rich blood.  The 
LAD travels in the interventricular groove and continues all the way down to the 
apex of the heart.  The LAD supplies most of the blood required by the left 
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ventricle.  The circumflex lies in the AV groove between the left atria and left 
ventricle. 
The coronary sinus vein returns most of the coronary venous blood from 
the left ventricle to the right atrium.  The coronary sinus returns approximately 
75% of the total coronary blood flow to the heart. 6  The coronary sinus is located 
in the right atrium and runs transversely in the groove between the left atrium and 
left ventricle.  It also prolongs down the posterior apex of the left ventricle.  Most 
of the coronary blood flow from the right ventricle returns to the heart through the 
anterior cardiac veins that flow directly into the right atrium. 
 
 
 
Figure 7 Coronary Veins of the Heart8 
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4.2 Coronary Artery Problems 
Coronary artery anomalies are rare.  Early detection and evaluation is 
essential because of its association with sudden cardiac death.  Today’s 
technology advancements with computer imaging have made it possible to detect 
coronary anomalies through the use of CT scans.  Coronary anomalies can be 
classified into anomalies of origin, the course, and termination.   These 
anomalies can be further classified as: 
1. Anomalies of the Origin9 
• Origin of coronary artery from pulmonary artery 
• Single coronary artery 
2. Anomalies of the Course9 
• Myocardial bridging 
• Duplication 
3. Anomalies of Termination9 
• Coronary artery fistula 
• Extra-cardiac termination 
 
Interarterial left coronary artery is the most common and clinically 
significant anomaly.  This is an anomalous origin of the left coronary artery 
coursing between the aorta and the pulmonary artery.  Patients with this anomaly 
frequently suffer sudden cardiac death.  
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Figure 8 Interarterial Left Coronary Anomaly9 
 
Another origin anomaly is known as “ALCAPA”.  In this anomaly, the left 
coronary artery begins only from the pulmonary artery. As a result, the left side of 
the heart is supplied with relatively low oxygenated blood under low pressure.  
This anomaly more than frequently leads to sudden cardiac death.  ALCAPA is a 
rare congenital anomaly accounting approximately 0.25% – 0.50% of all 
congenital heart diseases.9  Approximately 85% of patients’ present clinical 
symptoms of congestive heart failure or CHF within the first 1-2 months of life.9 
 
 
Figure 9 ALCAPA Coronary Anomaly9 
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An anomaly of the course is myocardial bridging.  This anomaly occurs 
when a section of the artery buries itself under the myocardium.  A normal 
healthy artery typically rest on top of the myocardium.  This is commonly 
observed in the left anterior descending (LAD) coronary artery.  If this happens, 
the depth of the artery under the myocardium is more important than the length 
of the myocardium bridging.  Clinicians are still debating whether myocardium 
bridging has any hemodynamic significance. 
 
 
Figure 10 Myocardial Bridging Coronary Anomaly9 
 
An anomaly of termination is called fistula.  This anomaly occurs when the 
LAD gives rise to a large septal branch that terminates in the right ventricle (see 
blue arrow in picture below).  In this case, the LAD bypasses the myocardial 
capillaries and terminates directly inside the heart chamber.  Major sites of fistula 
are the right coronary artery (40-60%), the LAD (30-60%), the circumflex, or a 
combination of both.10  About 90% fistulas terminate on the right side of the heart 
and in rare occasions on the left side or the pericardium.  Of the right side 
termination anomalies, the most frequent occur in the right ventricle followed by 
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the right atrium.  Small fistulas are typically benign and can only be detected in 
routine echocardiograms or autopsies.  On the other hand, larger fistula can 
progressively enlarge and lead to CHF and myocardium infarctions.  It can 
potentially be deadly in older patients. 
 
 
Figure 11 Fistula Coronary Anomaly9 
 
The human body is a precisely engineered machine that works in synergy 
with multiples systems.  When one system fails, health issues may develop that 
could lead to death.  Any of the above mentioned coronary ailments can lead to 
congestive heart failure or sudden death.  Cholesterol buildup in the coronary 
arteries may prevent sufficient blood from reaching the heart tissue.  Often 
enough, this condition leads to chest pain.  If the blood supply is completely 
obstructed, a heart attack may occur.  The coronary disease may contribute to 
high blood pressure which in time can lead to CHF.  Heart valve problems can 
also lead to CHF.  When the valves do not work properly, the heart muscle has to 
work harder to keep the blood flowing. 
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Chapter 5: Congestive Heart Failure 
 
 
5.1 Definition of Congestive Heart Failure 
What is congestive heart failure?  Congestive heart failure or CHF is a 
condition in which the heart can no longer pump enough blood to the rest of the 
body.  It is a heart disease that can affect the right ventricle, the left ventricle, or 
both.  It is most commonly a chronic condition that develops overtime, but it can 
also happen suddenly in rare cases.  When CHF affects the right heart side, the 
right ventricle loses its ability to pump blood to the lungs.  A common symptom of 
right side failure is the swelling of the feet and lower legs.  As the condition 
worsens, the upper legs swell and eventually the swelling moves to the abdomen 
area.  When heart failure affects the left side, the left ventricle decreases its 
ability to pump blood to the body.  The left ventricle receives highly oxygenated 
blood from the lungs ready to be distributed throughout the body.  A common 
symptom of left side heart failure is breathing difficulty.  As the left ventricle fails 
to empty its chamber, fluid starts collecting in the lungs which may lead to 
“pulmonary edema” if left untreated.  The extra fluid in the lungs or “congestion” 
prevents the airways to expand normally as a person inhales.  This creates the 
shortness of breath especially when the person is being active. 
Heart failure is classified by two stages.  It can either be systolic or 
diastolic heart failure.  Systolic heart failure is diagnosed when your heart can no 
longer pump or eject enough blood out of the heart efficiently.  Diastolic heart 
failure is diagnosed when your heart ventricles do not fill up with enough blood to 
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pump out.  In most cases, the heart can contract normally but it has become stiff 
and less compliant.  In either case, the danger is that your heart cannot pump 
enough blood to the rest of the body, especially when the person is active.  As 
the pumping ability of the heart is diminished, blood may start to back up in 
different areas of the body producing congestion of the lungs, the liver, and the 
body’s extremities like arm and legs.  As a result, there is a lack of oxygen being 
supplied to these organs or body cells which reduces their ability to function 
properly.  The long term prognosis can be deadly as organ failure may be the 
result of an untreated condition. 
A common clinical measurement for the heart’s ability to pump blood 
effectively is called the “ejection fraction” or “EF”.  The ejection fraction is a 
calculation of how much blood is ejected from the left ventricle, also known as 
“stroke volume”, divided by the maximum volume remaining in the left ventricle at 
the end of the relaxation phase or “diastole”.  A normal ejection fraction is greater 
than 50%.6,11   Systolic heart failure is diagnosed when the EF is less than 50%.  
In diastolic heart failure, the ejection fraction is typically normal.  Diastolic heart 
failure is more common in patients older than 75 years, especially in women who 
suffer from high blood pressure. 
Heart failure affects 1% of people aged 50 years, about 5% of those aged 
75 years or older, and 25% of those aged 85 years or older.11  As the expectancy 
living age increases, the number of elders will also increase.  This number is 
continually increasing therefore the number of people diagnosed with heart 
failure will also rise.  In the United States nearly 5 million people live with heart 
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failure.  And every year about 550,000 new cases are diagnosed.11  The rate of 
death from heart failure is about 10% after the first year being diagnosed.  About 
50% of people with CHF will die within 5 years after being diagnosed.11  This 
statistics do vary by patient’s exact diagnosis and therapy, nonetheless it is 
classified as a high death risk disease.  Many advances have been made in 
research and development for new therapies, both in drug or medical device 
treatments.  This is a welcome sign of relief for patients who have to live with this 
life debilitating condition. 
 
5.2 What Causes Congestive Heart Failure?   
Congestive heart failure is not a disease but rather a syndrome that can be 
developed by several factors.  CHF is a weakening of the heart caused by the 
following or a combination of several: 
• Weakened heart muscle: the heart muscle can become weak because 
of damage and thus loose its capability to contract as it should.  This 
damage to the muscle more often enough occurs from coronary artery 
problems. 
• Damaged heart valves: valves in the heart allow blood to flow in one 
direction only.  When these fail, blood may flow back or not enough 
through the valve.  An incompetent valve is a valve that does not close 
properly and allows blood to flow backwards in the heart.  The heart then 
needs to work extra hard to keep the same blood output to the rest of the 
body.  A stenotic valve is a valve that does not open properly restricting 
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the blood flow through the narrow opening.  The heart has to work harder 
to ensure enough blood passes between the chambers and to the rest of 
the body. 
• Blocked coronary vessels:  the coronary arteries provide the blood to 
the heart for it to work properly.  If the heart does not get its normal supply 
of oxygenated blood, it may in turn start to fail. 
• Toxic exposure: excessive intake of drugs 
• Infections 
• High blood pressure: increase blood pressure in the circulatory system 
can lead to an increased heart size or thickened left ventricular wall.  This 
condition reduces the compliance of the ventricle wall and the ventricle’s 
ability to contract. 
• Prolonged arrhythmias: slow weakening of the heart 
 
Congestive heart failure can also developed by lifestyle choices.  Unhealthy 
habits such as smoking or excess use of alcohol can lead to heart failure.  An 
unhealthy diet and a lack of exercise that leads to obesity can contribute to heart 
failure.  Not because of increased weight but rather the accompanying factors of 
obesity such as increased blood pressure and diabetes. 
 
5.3 How to Treat CHF? 
The treatment of CHF depends on the exact cause and it can usually be 
treated effectively.  The overall goals of the treatment are to correct the 
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underlying causes, relieve the symptoms, and prevent further damage to the 
heart.   In order to determine the best treatment option, physicians usually 
classify the type of CHF according to the New York Heart Association (NYHA) 
classification system.   
 
Table 1 The Stages of Heart Failure - NYHA Classification13 
 
Class Patient Symptoms 
Class I (Mild) No limitation of physical activity. 
Ordinary physical activity does not 
cause undue fatigue, palpitation, or 
dyspnea (shortness of breath). 
Class II (Mild) Slight limitation of physical activity. 
Comfortable at rest, but ordinary 
physical activity results in fatigue, 
palpitation, or dyspnea. 
Class III (Moderate) Marked limitation of physical activity. 
Comfortable at rest, but less than 
ordinary activity causes fatigue, 
palpitation, or dyspnea. 
Class IV (Severe) Unable to carry out any physical 
activity without discomfort. Symptoms 
of cardiac insufficiency at rest. If any 
physical activity is undertaken, 
discomfort is increased. 
 
 23 
Chapter 6: Cardiac Resynchronization Therapy 
 
 
6.1 Definition of CRT 
One way to treat heart failure is to place a device in the chest to assist 
with the electrical activity of the heart.  People who suffer from heart failure 
normally develop a problem with their heart’s electrical function.  Whereas 
traditional devices only applied therapy to treat electrical anomalies of the right 
side of the heart, a new type of therapy called cardiac resynchronization (CRT) is 
available for heart failure patients.  CRT involves the use of electrical signal to 
stimulate and pace both the right and left ventricles.  Roughly three to four out of 
every ten people with heart failure have an electrical problem in the conduction of 
electrical impulses to the lower chambers of the heart.12 
Cardiac resynchronization therapy is a fairly new type of treatment.  The 
first implantable device supporting CRT therapy was introduced by Medtronic in 
2001.  It was a CRT pacemaker or CRT-P called InSync®.  Since then, the 
technology has evolved to include ICDs that can also deliver CRT therapy.     
The concept behind cardiac resynchronization therapy is very simple.  It attempts 
to restore the normal coordinated pumping action of the right and left ventricles of 
the heart by correcting the electrical problems associated with CHF.  Typically, 
electrical problems arise from conduction blocks on the bundle branches which 
create contraction delays between the ventricles.  The result is an asynchronous 
contraction of the ventricles which reduces the pumping ability of the heart.  By 
restoring the synchrony of the heart chambers, CRT is perhaps controlling future 
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progression of CHF that can lead to more severe problems.  Ultimately, CRT is 
bringing an improved quality of life by treating the symptoms associated with 
CHF.    
There are two types of CRT devices available.  The first one delivers only 
electrical signals and is called a CRT pacemaker.  The other combines a 
pacemaker with a defibrillator for those patients who are at high risk of sudden 
cardiac death due to a fast heart arrhythmia.  A defibrillator is a device commonly 
used to shock patients out of a deadly fast rhythm.  This device is called a CRT 
implantable cardioverter defibrillator or CRT ICD. 
The CRT system consist of three parts, the pulse generator which delivers 
the electrical signals, the lead which carry the electrical signals from the 
generator to the heart, and the lead electrodes which transmit the signals to the 
heart. 
 
Figure 12 CRT-D Device and Leads Implanted Inside the Heart 
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A non CRT pacemaker usually has two electrical leads going from the 
device to the heart, one placed in the right atrium and another placed in the right 
ventricle.  These two electrical leads will ensure the heart maintains a normal 
coordinated pumping relationship between the upper and lower chambers.  A 
CRT device has an additional electrical lead that connects the device to the left 
ventricle.  This third lead is routed through the coronary sinus and placed on the 
outer surface of the left ventricle.  The third lead allows the device to coordinate 
the electrical stimulus of the left ventricle and bring both ventricles back into a 
synchronous pumping action.  This type of therapy is sometimes referred as “bi-
ventricular” or “bi-v pacing” because both ventricles are being stimulated. 
The development of CRT arose from the studies that showed 40% of CHF 
patients had an interventricular electrical conduction problem.  This condition 
often led to worsening CHF symptoms that terminated in death.  A typical 
candidate that would benefit from CRT suffers from NYHA class III or class IV 
heart failure and their ejection fraction is below 50%. 
 
6.2 CRT Benefits 
Many clinical trials have been performed to prove the benefits of cardiac 
resynchronization therapy.  The results of these trials over the last decade have 
shown reduction in hospitalization occurrences and mortality rate on patients who 
received CRT. 
The MIRICLE clinical trail sponsored by Medtronic evaluated the effects of 
CRT on quality of life and symptoms in patients with moderate or severe heart 
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failure.  The trial examined the safety and efficacy of CRT combined with 
traditional ICD therapy.  The results found an improved quality of life after six 
moths of combined CRT and ICD therapy as evaluated by the “Minnesota Living 
with Heart Failure Questionnaire”.  The results also showed improved functional 
capacity and exercise tolerance in patients with advanced HF.  However, the trial 
endpoints did not include mortality or hospitalization measurements.  The safety 
and efficacy of CRT was raised in part due to questions with lead placement and 
possible interference from the addition of bi-v pacing and ICD therapy.  The trial 
showed that CRT does not interfere in the delivery shock therapy but concluded 
that left ventricular lead placement is not without its challenges.  Transvenous LV 
lead implantation was unsuccessful in 12% of the patients in the study.14  It was 
also noted that once implanted, LV leads were prone to dislodgement.   
The COMPANION study was the largest CRT device trail and the first 
designed to study the mortality and hospitalization rates as the primary 
endpoints.  It was originally forecasted that up to 2200 patients would be 
required, although that study was conducted with 1634 patients. All the patients 
in the study were under optimal pharmacological therapy (OPT) with the 
additional therapy of CRT-P or CRT-D for a selected group.  The primary 
endpoint of death or any hospitalization showed a reduction of about 19% for 
both CRT-P and CRT-D patients as compared to the OPT alone therapy 
patients.15  The secondary endpoint of all cause mortality showed a reduction of 
24% for CRT-P vs. OPT and a reduction of 43% between CRT-D vs. OPT.15  The 
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results of the COMPANION trial gave additional proof regarding the benefits of 
CRT . 
Additional clinical trials like the MUSTIC trial and the CARE-HF trial have 
provided additional data supporting the value of CRT.  The MUSTIC results 
concluded that CRT improved exercise tolerance and quality of life for patients 
with chronic heart failure and interventricular conduction delay.  The trial also 
concluded a 66% reduction in hospitalization occurrences due to heart failure 
complications.16  The CARE-HF trial also focused on mortality and hospitalization 
as endpoints for CRT benefit.  The trial compared CRT to normal OPT treatment 
in 813 patients.  The trial showed a reduction of 46% in combined death or heart 
failure hospitalization.  CRT was also associated with a 37% reduction in the risk 
of mortality.17 
 Cardiac resynchronization therapy can substantially improve the quality of 
life for patients suffering from NYHA class III or class IV heart failure.  The 
physiological benefits of CRT can be seen in the improved tolerance for 
exercising.  Additionally, CRT has proven to reduce the rate of mortality and 
decrease the occurrence of hospitalization. 
 
6.3 CRT and LV Pacing Complications 
The benefits of CRT to treat congestive heart failure are numerous, 
however there is much work to be done to increase the efficacy and optimization 
of this therapy.  Several challenges associated with individual’s anatomies make 
the delivery of CRT more troublesome.  Differences in patient’s coronary system 
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anatomy make it difficult for physicians to implant an LV lead through the 
coronary sinus.  In such cases, these patients are eliminated from candidacy for 
traditional CRT.  In other instances, although the majority of the population has a 
normal working coronary system, small anatomical differences in the coronary 
vein produce a challenge to the implanting physician to locate the LV lead 
appropriately.  These challenges are associated with differences in the vein 
diameters and vessel turns.  The implant procedure for an LV lead is more 
challenging because physicians must locate a region where good capture 
thresholds can be achieved and the site of most delay for left ventricular 
mechanical activation.18  Without a well positioned LV lead, CRT devices lose 
their ability to perform cardiac resynchronization.  Other complications with LV 
implant include lead dislodgement, coronary sinus thrombosis, loss of pacing 
capture, and stimulation of the diaphragm. 
 Other treatment methods are constantly being developed and tested to 
provide alternative pacing options to the left ventricle.  In an effort to maximize 
hemodynamic benefit of CRT, the use of an epicardial LV lead may be an option.  
An epicardial lead is surgically attached directly to the epicardium of the heart.  
This procedure requires a thoracotomy and general anesthesia as compared to 
local anesthesia for traditional CS LV leads.  Once access to the heart is 
obtained, the physician maps the best LV site for optimal pacing thresholds.  The 
lead is actively affixed with sutures to the epicardium and tunneled sub-muscular 
to the device pocket.  Epicardial leads have shown excellent long term pacing 
results with less lead complications when compared to CS LV leads.  Although 
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epicardial leads are associated with major surgery, it has been shown to be safe 
and extremely reliable.  Coronary sinus LV lead implantation may be the primary 
option for most patients, but for a substantial subset of patients an epicardial lead 
may provide the benefits necessary for successful CRT.  
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Chapter 7: Epicardial Pacemaker 
 
 
7.1 Overview of Traditional CRT Therapy 
 Cardiac resynchronization therapy attempts to restore the synchronous 
pacing of both ventricles.  First a pacemaker, along with right and left side leads 
must be implanted.  A CRT system consists of a pulse generator and three 
pacing leads.  The generator contains a battery and microelectronic computer 
that serves as the “devices” brain.  The leads are insulated wire coils that carry 
electrical impulses produced by the pulse generator to the heart and carry 
information from the heart back to the pulse generator.  In a CRT system, one 
lead goes to the right atrium, the second lead to the right ventricle, and the third 
lead to the left ventricle.  Right heart leads are implanted intravenously via the 
superior vena cava and anchored to the endocardium of the heart.  CRT left side 
leads are most commonly implanted via the coronary sinus to the post lateral 
side wall of the left ventricle.  Many clinical trials have shown the benefits of CRT 
for patients suffering from NYHA class III or class IV heart failure.  These CRT 
candidates can benefit from ventricle resynchronization by ways of an improved 
quality of life and less hospitalization events arising from HF complications. 
 Although it is generally true that CRT patients tend to be older, CRT 
device implants can also be performed in young adults.  It is possible to have an 
electrical defect in the heart without having any other heart problem.  The natural 
pacemaker may fail for unknown reasons establishing an ectopic site for the new 
pacemaker.  With today’s advancement in technology, if no other physical 
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limitation is present, it is possible for anyone with a CRT device to live a normal 
active life. 
 Several methods of implanting a CRT system are available.  The choices 
depend primarily upon health, age, and patient’s anatomy.  The most common 
involves implanting the insulated leads into the heart through the veins of a 
patient who is under mild anesthesia.  The pulse generator is implanted under 
the skin in a specially prepared pocket in the right or left upper chest.  The leads 
are connected to the pulse generator and the device secured to the pocket by 
sutures.  This surgery typically takes about 2 hours and it is often performed in a 
cardiac lab.  Fifty percent of this time is usually spent locating the appropriate LV 
lead site and advancing the lead.  Another method involves the use an of 
epicardial lead instead of a transvenous LV lead.  The implantation procedure for 
an epicardial lead requires extensive surgery and is performed with the patient 
under complete anesthesia. 
 
7.2 The Epicardial Satellite Pacemaker Concept 
 The epicardial satellite pacemaker concept was developed to address 
major challenges seen today to gain left side pacing access for CHF patients.  
The concept is a collection of the benefits seen from coronary sinus implants and 
epicardial lead implants.    Biventricular pacing has proven to be an effective 
therapy for treating patients with congestive heart failure.  Unfortunately when 
trying to implant a CRT system, occasionally it may be difficult to gain access to 
the left side of the patient’s heart through the coronary sinus (CS).  This problem 
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could be associated with a small CS diameter which prevents lead advancement.  
The trajectory of the CS could be abnormal whereas it prevents establishing an 
optimal LV pacing site or the physician may not be able to keep the lead in a 
stable position.  An epicardial lead surgically attached to the heart addresses the 
above concerns.  However, this procedure requires major surgery and prolonged 
recovery times for the patient.   The epicardial satellite pacemaker concept is 
intended to resolve the conduction problems, anatomical differences within 
patients, and the surgical risks and side effects associated with a thoracotomy. 
 
7.3 How the Epicardial Pacemaker Works 
 A CRT system is an implantable cardiac system that treats patients with 
congestive heart failure (CHF).  This particular cardiac system is composed of a 
master device, intravenous leads, and a satellite pacing device.  The master 
device provides the pacing pulses to the right side of the heart via transvenous 
leads anchored to the endocardium of the heart.  The master device also 
contains a communication module that sends pacing commands to the satellite 
device.   The satellite device is a leadless pacing output device anchored directly 
to the left ventricular epicardial wall of the heart.  This satellite device mentioned 
above is the epicardial pacemaker or EPI pacemaker. 
 Figure 13 shows a CRT system comprised of the master & epicardial 
pacemaker device.  The master device (item 102) is shown connected to the 
heart through traditional intravenous lead (items 112 & 114).  The EPI 
pacemaker (106) is shown directly attached to the left ventricle.  This cardiac 
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system supports multi chamber detection and stimulation therapy, including 
biventricular pacing to treat a patient with CHF.  The EPI pacemaker can be 
implanted onto the left ventricle using thoracoscopic procedures during implant of 
the master device.  In special events, the EPI pacemaker may be implanted 
using prophylactic techniques during bypass heart surgery or in cases where 
heart access is available.  The EPI pacemaker communicates with the master 
device using wireless communication methods like RF.  This is represented by 
link 110.  The EPI pacemaker is not intended to deliver shock therapy, but in 
cases where a CRT-D device is used as the master unit, the EPI pacemaker may 
contribute to shock therapy by enabling better detection of arrhythmias.  By 
noting ECM irregularities between the EPI pacemaker and the right ventricle 
lead, fibrillation may be able to be detected with confidence. 
 
 
 
 
 
 
 
 
 
 
 Figure 13 CRT Cardiac System with Epicardial Satellite Pacemaker19 
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The EPI pacemaker is capable of pacing the left ventricle under direct 
command of the master device.  Depending on its programmable settings, the 
EPI pacemaker may be set to respond to various inputs.  It may be programmed 
to directly pace according to an output set by the master device or it may be 
programmed to sense artifacts from the right ventricle lead and apply a pacing 
pulse in response.  Yet another programming setting could be a combination of 
both, sensing artifacts and direct commands from the master device. 
 
7.4 Description of the Epicardial Pacemaker 
 In its most simple embodiment and functionality, the EPI pacemaker is a 
passive device.  It is configured to only pace the left ventricle in response to 
commands from the master device.  The EPI pacemaker has a housing made out 
of commercially pure titanium.  The housing protects the microelectronic 
components in addition to holding the battery in place.  The housing is internally 
insulated by polyimide tape to prevent shortening of the battery.  In addition to 
the battery, the housing contains all the electronic components  
 
 
Figure 14 Epicardial Satellite Pacemaker 
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 The EPI pacemaker also includes a battery to supply operating power to 
all the electrical components.  The battery is capable of operating at low current 
drains for long periods of time.  The battery is also capable of providing pulses 
with sufficient voltage to stimulate the left ventricle.  
 
 
Figure 15 Battery for Epicardial Satellite Pacemaker 
 
 The microelectronics of the EPI pacemaker is considered the brain of the 
device.   It is tasked for receiving signals from the master device and in turn 
producing a pacing output to stimulate the left ventricle.   It consists of a single 
layer PCB, a PIC controller and a capacitor. 
 
 
Figure 16 Electronics for Epicardial Satellite Pacemaker 
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An electrode is mounted to the front surface of the device to deliver the 
pacing pulses.  The electrode has a helical shape to facilitate perforation of the 
pericardium and to be screwed into the epicardium.  Additionally, it provides an 
active fixation anchor to the heart tissue.  The electrode is assembled to a 
titanium lid by brazing a ceramic ring to isolate the two metals.  The helical 
electrode is made of 80% platinum and 20% iridium. 
 
 
Figure 17 Epicardial Satellite Pacemaker (Exploded View) 
 
7.5 Benefits over Traditional CRT Leads 
Within the same CRT system, multiple epicardial pacemakers may be 
used.  A physician may elect to implant multiple EPI pacemakers at different 
locations of the heart.   This approach gives the physician the ability to determine 
which one is the most effective at applying the pacing pulses.  In another 
instance, the physician may elect to implant multiple EPI pacemakers in physical 
proximity to each other.  Initially all the EPI pacemakers can be turned off, and 
after implantation is complete, activate one at a time.  As the battery runs low on 
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the active EPI pacemaker, that particular one can be turned off and a new one 
activated.  
 Another benefit of an EPI pacemaker cardiac system is multi-site pacing.  
The system can be configured to support triple timing ventricular pacing to obtain 
optimal heart hemodynamics.   One EPI pacemaker can be positioned one 
centimeter down from the ventricular base by the cardiac vein.  A second EPI 
pacemaker can be positioned 3 centimeters down by the same vein.  Then, the 
first EPI pacemaker is paced and the second one paced 10 milliseconds later.  
Finally, the RV tip electrode is paced 15 milliseconds later.  This pacing method 
is extendable to four or more EPI pacemakers if desired. 
The ability to implant the EPI pacemaker using thoracoscopic procedures 
is a great improvement over thoracotomy procedures needed for an epicardial 
lead.  Because the EPI pacemaker is wireless, there is no need for tunneling the 
lead to the device pocket.  Therefore the EPI pacemaker can be implanted using 
thoracoscopy over thoracotomy.  This minimizes trauma to the patient and 
reduces recovery periods.  In addition, a thoracoscopy can be performed under 
minimal sedation and local anesthesia as compared to general anesthesia 
needed in a thoracotomy. 
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Chapter 8: Future Work 
 
 
8.1 Vibration Studies on the Heart Tissue 
 The heart is a muscle that is constantly in motion.  A normal heart beats 
an average of 60-70 beats per minute.  Under stressful conditions from 
exercising, the rate can increase to 130-150 beats per minute.  An active fixation 
of the epicardial pacemaker is essential for continuous therapy to the left 
ventricle.  The thickness of the epicardium and myocardium is approximately 1.5 
centimeters.  Therefore, a relatively small helix is desirable to minimize 
perforation of the heart muscle and reduce trauma.  On the negative side, it 
provides less tissue capture to secure the device to the heart wall.  Vibration 
tests need to be performed with canine or pig hearts to determine the relationship 
between excitation frequency and electrode length.  
The epicardial pacemaker is intended to be implanted using a 
thoracoscopic procedure.  This means the physician needs to deliver the device 
through the rib cage and affix it to the epicardium.  One unknown factor is the 
amount of torque required to screw the device to the epicardium.  This 
measurement can also have substantial impact on the design of the helical 
electrode. 
 
8.2 Signal Resistivity Measurements for RF Communication 
 RF communication is more efficient in a less conductive environment such 
as air.  Air has very high resistivity thus it makes it easier to communicate at 
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higher frequencies.  The human body, on the other hand, is very conductive.  
The distance between the master device and the epicardial device and the total 
resistivity between the two can affect how the two devices communicate.  
Scientific studies have estimated resistivity values of the myocardial tissue.  One 
study determined that with 100Hz stimulation at 2 V, myocardial resistivity was 
approximately 295 Ω•cm.  Based upon resistivity, we can estimate the predicted 
resistance of tissue between the master device and the epicardial pacemaker 
  (20) 
 
  
   
 (20) 
  
Assuming a 1.5cm myocardium thickness and a 10 cm ventricular myocardium 
width, the area (A) is 15cm2.  Assuming an average distance of 20 cm from the 
master device pocket to the epicardial pacemaker, the predicted resistance can 
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be calculated to be 393.3 Ω.  The further the master device is from the epicardial 
pacemaker, the larger resistivity between the two.  In a similar manner, the 
heavier the patient, the more fatty tissue present between both devices.  These 
values are low in comparison to other RF applications which could limit the 
communicating effectiveness.  These initial differences could be resolved by 
programming capabilities within the master device.  But in time, if patient’s 
resistivity fluctuates, communicating frequencies may vary which will require 
physician intervention.  The danger is for pacer dependent patients where the 
possibility of losing communication between devices and not delivering therapy 
may occur. 
 
8.3 Gel to Promote Adhesion and to Reduce Scar Tissue 
 One potential problem with the epicardial pacemaker and its screw in 
electrode is irritation to the heart tissue that occurs due to the movement of the 
electrode as the heart beats.  This irritation causes the body to build scar tissue 
around the affected area, in this case around the electrode.  As scar tissue builds 
up, higher voltages are required to pace the heart.  This could result in lower 
battery life for the epicardial pacemaker and perhaps the need for more frequent 
replacements. 
 To alleviate this problem, a soft gel material can be affixed to the outer 
face of the lid surrounding the electrode (figure 18).  This gel-like material may be 
affixed to the lid by any well known medical adhesives.  This material can serve 
multiple purposes.  The gel can facilitate attachment of the epicardial pacemaker 
 41 
to the heart tissue and absorb shocks as the heart beats and moves.  The gel 
material can also promote tissue growth and allow tissue to grow into the gel to 
hold and anchor the device to the heart muscle.  The gel material may also 
contain a steroid, such as dimethyl sulfoxide (DMSO) to reduce the immune 
response of the body and aid in preventing irritation and inflammation to the 
implant area.19  
 
 
 
 
 
 
 
 
 
 
8.4 Future Design Considerations (The Pericardium) 
  Although the benefits of an epicardial pacemaker seem to provide a safe 
and viable option to traditional transvenous LV leads, the approach has its 
challenges.  These include whether the pericardium needs to be surgically 
opened and closed after implant.  The pericardium serves several mechanical 
functions.  Besides constraining the heart in the thoracic cavity, it has 
hemodynamic influences on the ventricles during diastolic filling.  Several studies 
Figure 18 Epicardial Pacemaker with Steroid Eluting Gel 
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have been done to assess the benefit of closing the pericardium or leaving it 
open after thoracotomy. 
One study concluded that pericardial closure is unlikely to have any 
significant harmful effects in the majority of patients who maintain a good 
circulatory state after surgery.  For these patients, it is reasonable to close the 
pericardium as long as the pericardium does not appear to be taut.  However, for 
ill patients who started with a low cardiac output, closure of the pericardium had 
adverse effects by reducing cardiac output as much as 14%.21   The study 
suggested that cardiac function may be impaired by pericardial closure after 
cardiac surgery because of some degree of constriction of the heart chambers.  
For these patients it was recommended to leave the pericardium open to avoid 
any further stress to the blood circulation. 
Another study showed the significant effect on diastolic filling of the left 
ventricle when the pericardium was closed.  However, when the pericardium was 
opened, it resulted in an increase cardiac index (cardiac output divided by body 
surface area).  The increases can be attributed to the Frank-Starling mechanism 
to increased left biventricular preload.22  With the pericardium open, the ventricle 
is less restricted and allowed to fill with more blood.  This in turn has an 
improvement in left ventricular systolic performance which should be considered 
when contemplating closure of the pericardium.23 
There have been several studies describing both the advantages and 
disadvantages of pericardial closure after heart surgery.  Pericardial closure may 
reduce the risk of myocardial injury.  This can be more beneficial in future 
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surgical interventions such as coronary artery by-pass.  However, it should be 
considered to be left open for patients who in early postoperative periods show 
impaired ventricular function.24 
 
8.5 Future Design Considerations (The Rib Cage) 
The rib cage is a bony structure that protects the heart, lungs, and other 
underlying organs.  It is made of three groups of bones, the sternum, twelve (12) 
pairs of ribs, and twelve (12) thoracic vertebrae.  Implantation of an epicardial 
pacemaker is desired to be accomplished by thoracoscopic procedures.  To 
accomplish this, the device needs to be small enough to pass through the 
intercostal spaces between the ribs. 
An intercostal space is wider in the upper ribs.  As we move down the rib 
cage, the intercostal spaces start to reduce in size.   One point to consider in 
making an incision through the intercostal space is the neurovascular bundle of 
vein-artery-nerve.  Therefore it is desired that the intercostal space be penetrated 
as low as possible.  This reduces the opening for the epicardial pacemaker to 
pass through.  Typically, epicardial leads are implanted through the fourth 
intercostal space.25, 26  It is desired that any thoracoscopic heart surgery to 
implant an epicardial pacemaker be performed also through the fourth intercostal 
space. 
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Figure 19 Intercostal Space in Human Ribs 
  
The initial design and prototyping of the epicardial satellite pacemaker 
have conceptually addressed its success.  A small device was fabricated capable 
of being programmed to deliver a constant 3V pulse.  Radio frequency 
communication capabilities on current pacemakers and implantable cardioverter 
defibrillators make them suitable candidates to function as a master device.  
Therefore, the foundation for a wireless epicardial pacemaker is feasible.  There 
is a lot of work and design refinement that needs to be done before we can move 
past conceptual phase and into testing trials.  Addressing the future work 
concerns will provide a better understanding of the work ahead to physically 
prove the benefits of a wireless epicardial pacemaker over traditional CRT. 
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Chapter 9: Conclusions 
 
 
 Although people are at a higher risk of developing CHF on the later years 
of life, heart failure is a disease that affects everybody without discrimination to 
gender or age.  Many drugs are available to address the symptoms, but the most 
successful therapy has been proven to be cardiac resynchronization.  CRT is a 
fairly young technology and it is constantly evolving to provide physicians with 
the best tools to treat CHF. 
 The epicardial wireless pacemaker concept takes a step in addressing 
today’s challenges with coronary sinus LV implants and epicardial leads.  By 
directly stimulating the heart tissue, we can obtain lower capturing thresholds.  
An epicardial pacemaker can also be positioned on the site for optimal ventricle 
stimulation regardless of coronary anatomies.  A plurality of epicardial 
pacemakers can be implanted to give physicians multisite pacing options.  
Finally, the lack of wires eliminates the need to tunnel from the implant site to the 
master device pocket.  This facilitates a less invasive surgical procedure to 
implant the device. 
 The concept is still in early development stages.  Several implant 
requirements need to be evaluated, primarily regarding electrode length.  The 
electrode is the direct connection to the heat tissue to pass the electrical signals 
of the device.  Electrode length is also critical for determining stability of the 
device after implantation.   In addition, resistivity measurements need to be 
mapped to develop signal algorithms capable of self-regulating changes to 
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maintain proper communication between devices.  The epicardial pacemaker 
concept so far has proven to be feasible, but much work is still needed to be 
developed to prove its efficacy to treat CHF. 
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